Member Info for TorquayFan

Yes WTP. For me, as often as not, we do get an RNS even though it might be just a 'poster' involved. It seems unusual to me, the short notice of this and after all, it's a 30 minute presentation which has been scheduled in. Good news!

I'm guessing today's RNS clears the way for more before Thursday.

Balerno 09.05 noted the arrival of commercial.enquiries@Scancell.co.uk and that's at least, another sign of the details coming together. ATB

Bazookajr - thanks for that.

EE I know it well enough. We had dinner in Pak nam Pran with Inan there one evening many years ago. Good seafood !

Thanks Cleaner. Re. "Just wondering why it’s not mentioned CEO of Scancell".

I'd guess the emphasis at this meet is the science so the Prof. I/D is appropriate.

C11 - thanks. If you are right that's great news - I'll try to contact Inan for comment.

Marcus posted on the other side (LF) :-

"This Bispecific could be `the Holy Grail'.

SC134 linked with scFv fragment of CD3 mAb – lead clinical candidate.

Excellent specificity – binds to SCLC but not any healthy tissue.

Immunohistochemistry on frozen tissue.

SC134-H activates T cells and kills tumour cells.

No cross reactivity with GM1 expressed on neuronal cells.

SC134 compares favourably to BMS mAb.

Have a look at these deals ;

HTTPS://www.nature.com/articles/d43747-021-00096-w "

EE I'm not sure if this clarifies your question but I'm sure our techies will add comment later. It does look interesting.

((In Thailand eh ? It's been raining here today so cool for a while. I'm guessing you are in Phuket or BKK. Have a good holiday, (if that's what it is). ))

Thanks Cleaner. Scancell in a rich sandwich of exalted company on that list.

Cleaner - re. your 08.51 on 1st March https://melanomafocus.org/wp-content/uploads/2024/02/MPC24-Virtual-Brochure-2024-1.pdf

I wonder if we can expect any sort of transcript of Ms. Danson's address and maybe of the ensuing discussion. Otherwise I'm not sure what can come out of this but maybe at the very least, it might help a little with recruitment to the trials? ATB

Chester I agree. And hopefully we'll get an RNS re. new Modi-1 data even before that presentation on April 23rd ?

C11 - branding? Nothing amiss about optimism anyway. I was trying to make the point that whilst on the one hand Scancell doesn't always make it's hoped for timelines, on the other hand, Scancell also bring us an occasional surprise.

RW thanks as usual - give it a break please.

Cleaner 08.51 - yes it will be a fascinating but highly charged process giving visibility of what's going on, to Patients . . . . data already available to us might raise an eyelid for them x

C11 10.21 - positive and well founded optimism. In truth I feel it is hard to predict where or when the next surprise, (a good one hopefully), may appear.

Ray 10.44 - agree 100% . . . . when the data ripens, we get it first.

Chester 10.49 - yes if there is new data by then, CEO will propound it.

GLA

Points from today :-

Mia 16.41 - "3 months to the day since we had the last SCIB1 trial patient update - must be due another v. soon."

Ray 16.47 - "It's worth just reiterating just how well the Scope trial is going from the 17th Jan RNS".

Ray 17.40 - "Remember that we are also promised the preliminary data from the Modi1 + 2CPIs cohorts later this year."

Balerno 16.15 - "So maybe another RNS tomorrow?" (re. Sarah Danson's address to Patients).

Bermuda's 20.55 response to Drac - "but their pipeline is" (unique).

And Cleaner and Chester in action too. A good day IMO. GLA

Balerno yes point taken and also, thanks to Dracula I suppose - because at least we got some chat here today . . . .

I was surprised to see NO posts at all on the ADVFN threads for one week now. But IMO, it's the lull before!

Bermuda - the time spans involved, the costs and the sheer difficulties of managing the intricate and grueling processes with the personalised vaccines, in any volumes at all, (as described here), seem to me to me to make pv as such, nonsense.

I read it all here and there. Surprised to see you. As you well know I was just playing with Drac but its good to see you posting . . .

Drac - the other way to look at that is, Scancell are not falling behind but are in pole position and poised to overtake, in the final furlong . . . .

As a consequence, the nonsense and impracticalities of personalised vaccines are then to be consigned to the deep!

Of course, fuller and accurate details would have been better BUT for me it was good to see Scancell at least getting any mention under that headline.

Maybe one of our techies could email the Journalist with more. Every little helps.

Thanks for that Cleaner - good to see Scancell in that update!

Try this for some fun https://youtu.be/058hmFtdBW8?t=10

Give it a little time . . . . same as Scancell

WTP now that's a smiley. This :) is not. Never mind.

WTP - I wouldn't try to draw any conclusions from this scant info. but you may be right that it's harder to find players in the deep science than it is in the financial arena.

"Sath must need urgent help" ?? MMMmmm - I doubt that comment.

Thanks for the reminder Cleaner. We might get a snippet or two out of that. ATB

Conz - yes indeed. Of course, that doesn't mean to say nothing is going on - I'm sure the Scancell team and the trial staff are flat out and have plenty to do.

Just a wait for news of trials, data and hopefully, deals ! GL

That's right Violin - awaiting data and deals, the SP is stuck and so it seems are the BB's ! Not much here and not much on 'Litter Free' either. PoG and the other ADVFN threads are moribund too. Across the boards we seem to be all talked out at the moment - but there'll be plenty to come later.

Marcus posted a few days ago - "I wonder how Modi-1 is going?

► Highly mutating tumours stimulate T cells, but these are switched off in the immunosuppressive tumour environment

► Checkpoint inhibitors can reinvigorate these T cells BUT most tumours do not stimulate strong responses, so checkpoint inhibitors don’t work

► Vaccines have potential to stimulate new T cells BUT most induce low potency CD8 T cells that do not kill tumours

► MODITOPE is unique in stimulating potent CD4 T cells against

stress-related post-translational modifications (siPTMs)

► These siPTMs are nature’s way of identifying stressed cells, such

as cancer cells

► The Modi-1 vaccine stimulates a strong pro-inflammatory

response and reverses the immunosuppressive tumour

environment

(Perhaps it will work best with Doublet PD-1 and CTLA-4)"

A nice reminder of Modi-1 news to come, but that's it !! ATB